Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist) monotherapy in patients with Wolfram syndrome type 1.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514909-64-00

Enrollment

Registered

2024-08-13

Start date

2024-05-16

Completion date

Unknown

Last updated

2024-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wolfram syndrome type 1

Brief summary

The percentage of participants with a positive response to MMTT (C-peptide at 90 min >0.6 ng/ml)

Interventions

DRUGMounjaro 7.5 mg solution for injection in vial

DRUGMounjaro 5 mg solution for injection in vial

DRUGMounjaro 2.5 mg solution for injection in vial

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The percentage of participants with a positive response to MMTT (C-peptide at 90 min >0.6 ng/ml)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026